Top

European Journal of Medical Research

Published in:

Open Access 01-12-2023 | Lung Cancer | Research

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors

Authors: Xu Li, Yeling Tang, Pengchen Liang, Miaomiao Sun, Tian Li, Zhiping Shen, Shuang Sha

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Yi Fei Qing Hua Granules (YQG) is a traditional Chinese herbal medicine with the effects of inhibiting the proliferation of lung cancer cells. Luteolin is one of the active compounds of YQG. Luteolin is a common flavonoid extracted from natural herbs and it can promote cancer cells apoptosis has been reported. However, the underlying molecular mechanism and effects of luteolin on human lung cancer needs to be validated.

Methods

Molecular docking, network pharmacology methods and quantitative structure–activity relationship (QSAR) model were used to identify the active components of YQG and their possible mechanisms of action. Western blot analysis was used to measure AR expression in A549 cells. Cell migration assays were used to detect A549 cells proliferation transfected by AR plasmid and AR mutation plasmid, respectively.

Results

TCMSP search results revealed that there are 182 active compounds in YQG, which correspond to 232 target genes. Sixty-one genes were overlapping genes in the 2 datasets of TCMSP and GeneCards. Through bioinformatics tagging of these overlapping genes, a total of 1,951 GO functional tagging analysis and 133 KEGG pathways were obtained. Through molecular docking technology and QSAR model verification, the multi-target active compound luteolin was screened out as one of the active components of YQG for in vitro verification. Androgen receptor (AR) was the hub protein with the highest docking score of luteolin. Western blot showed that luteolin could inhibit AR protein expression in lung cancer cell line A549. After the phosphorylation site of AR protein 877 was inactivated, the ability of luteolin to inhibit the proliferation of lung cancer cells was weakened. Luteolin significantly inhibited the growth of A549 xenogeneic tumors at day 25 and 28 and inhibited the expression of AR.

Conclusion

In this study, we have explored luteolin as one of the active components of YQG, and may inhibit the proliferation and migration of A549 cells by decreasing the expression of AR and the regulation of phosphorylation at AR-binding sites.

Cai L, et al. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. J Immunother Cancer. 2019;7(1):198.CrossRefPubMedPubMedCentral

Xu Y, et al. Deep learning predicts lung cancer treatment response from serial medical imaging. Clin Cancer Res. 2019;25(11):3266–75.CrossRefPubMedPubMedCentral

Yang L, et al. SIK1-LNC represses the proliferative, migrative, and invasive abilities of lung cancer cells. Onco Targets Ther. 2018;11:4197–206.CrossRefPubMedPubMedCentral

Chaft JE, et al. Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non-small cell lung Cancers: The NEOSCAN trial. J Thorac Oncol. 2016;11(4):537–44.CrossRefPubMed

Huang H, et al. Advances in molecular mechanisms for traditional Chinese medicine actions in regulating tumor immune responses. Front Pharmacol. 2020;11:1009.CrossRefPubMedPubMedCentral

Cao C, Wang Q, Liu Y. Lung cancer combination therapy: doxorubicin and β-elemene co-loaded, pH-sensitive nanostructured lipid carriers. Drug Des Dev Ther. 2019;13:1087–98.CrossRef

Zhang Y, et al. Chinese herbal medicine Wenxia Changfu formula reverses cell adhesion-mediated drug resistance via the integrin β1-PI3K-AKT pathway in lung cancer. J Cancer. 2019;10(2):293–304.CrossRefPubMedPubMedCentral

Yao J, et al. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: Study protocol of a multicenter randomized clinical trial. Trials. 2020;21(1):309.CrossRefPubMedPubMedCentral

Wang Q, et al. Adjuvant chemotherapy with Chinese herbal medicine formulas versus placebo in patients with lung adenocarcinoma after radical surgery: a multicenter, randomized, double-blind, placebo-controlled trial. Biol Proc Online. 2020;22:5.CrossRef

10.

Li FF, Wu H, Zhou B. Effect of Yifei Qinghua granule on VEGF, bFGF, angiostatin, and endostatin in Lewis lung cancer mice: an experimental study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33(8):1086–92.PubMed

11.

Miro C, et al. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022. https://doi.org/10.1016/j.canlet.2022.215581.CrossRefPubMed

12.

Torabinejad S, et al. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications. Eur Thyroid J. 2023. https://doi.org/10.1530/ETJ-22-0228.CrossRefPubMedPubMedCentral

13.

Blaszczyk N, et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res. 2004;10(5):1860–9.CrossRefPubMed

14.

Shang N, et al. Focal adhesion kinase and beta-catenin cooperate to induce hepatocellular carcinoma. Hepatology. 2019;70(5):1631–45.CrossRefPubMed

15.

Pisano C, et al. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: current and future clinical implications. Critical Rev Oncol Hematol. 2021. https://doi.org/10.1016/j.critrevonc.2020.103185.CrossRef

16.

Kim TJ, Lee YH, Koo KC. Current status and future perspectives of androgen receptor inhibition therapy for prostate cancer: a comprehensive review. Biomolecules. 2021. https://doi.org/10.3390/biom11040492.CrossRefPubMedPubMedCentral

17.

Lin CY, et al. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5. Cancer Sci. 2018;109(11):3564–74.CrossRefPubMedPubMedCentral

18.

Zheng L, et al. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR. Cancer Biol Ther. 2020;21(1):34–42.CrossRefPubMed

19.

Brennan S, et al. Androgen receptor as a potential target in non-small cell lung cancer. Cancer Res. 2017. https://doi.org/10.1158/1538-7445.AM2017-4121.CrossRefPubMedPubMedCentral

20.

Liu P, et al. The applications and obstacles of metabonomics in traditional Chinese medicine. Evidence-based Complem Altern Med. 2012;2012: 945824.

21.

Tsui K-H, et al. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. Int J Cancer. 2012;130(12):2812–23.CrossRefPubMed

22.

Selvi RB, et al. Inhibition of p300 lysine acetyltransferase activity by luteolin reduces tumor growth in head and neck squamous cell carcinoma (HNSCC) xenograft mouse model. Oncotarget. 2015;6(41):43806–18.CrossRefPubMedPubMedCentral

23.

Jiang Z-B, et al. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021;515:36–48.CrossRefPubMed

24.

Choi H-J, et al. Luteolin inhibits recruitment of monocytes and migration of Lewis lung carcinoma cells by suppressing chemokine (C–C motif) ligand 2 expression in tumor-associated macrophage. Biochem Biophys Res Commun. 2016;470(1):101–6.CrossRefPubMed

25.

D’Arrigo G, et al. Binding of androgen- and estrogen-like flavonoids to their cognate (non)nuclear receptors: a comparison by computational prediction. Molecules. 2021. https://doi.org/10.3390/molecules26061613.CrossRefPubMedPubMedCentral

26.

Sakkiah S, et al. Structural changes due to antagonist binding in ligand binding pocket of androgen receptor elucidated through molecular dynamics simulations. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.00492.CrossRefPubMedPubMedCentral

27.

Osguthorpe DJ, Hagler AT. Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry. 2011;50(19):4105–13.CrossRefPubMed

28.

Siddiqui IA, et al. Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J. 2011;25(4):1198–207.CrossRefPubMedPubMedCentral

29.

Meng GM, et al. Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cells through the activation of MEK/ERK signaling pathway. Chem Biol Interact. 2016;257:26–34.CrossRefPubMed

30.

Zhan G, et al. Antitumor, antioxidant, and nitrite scavenging effects of Chinese Water Chestnut (Eleocharis dulcis) Peel Flavonoids. J Food Sci. 2016;81(10):H2578–86.CrossRefPubMed

31.

Hong Z, et al. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance. Br J Pharmacol. 2014;171(11):2842–53.CrossRefPubMedPubMedCentral

32.

Wu YT, et al. Luteolin inhibits vascular smooth muscle cell proliferation and migration by inhibiting TGFBR1 signaling. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01059.CrossRefPubMedPubMedCentral

33.

Chang C, et al. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33(25):3225–34.CrossRefPubMed

34.

Gockel LM, et al. Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models. Arch Pharm. 2022;355(5): e2100467.CrossRef

35.

Zhou J, et al. miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer. Mol Ther Nucleic Acids. 2021;23:1217–28.CrossRefPubMedPubMedCentral

Title: Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors
Authors: Xu Li
Yeling Tang
Pengchen Liang
Miaomiao Sun
Tian Li
Zhiping Shen
Shuang Sha
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01302-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Luteolin inhibits A549 cells proliferation and migration by down-regulating androgen receptors

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Diagnosis, pathophysiology and preventive strategies for cardiac surgery-associated acute kidney injury: a narrative review

Lymphangiogenesis in gastric cancer: function and mechanism

Identification of hub genes and their correlation with immune infiltrating cells in membranous nephropathy: an integrated bioinformatics analysis

Correction: Protective effects of paraoxonase-1, vitamin E and selenium, and oxidative stress index on the susceptibility of low density lipoprotein to oxidation in diabetic patients with/without coronary artery disease

The characteristics of extrachromosomal circular DNA in patients with end-stage renal disease

A comprehensive review of the family of very-long-chain fatty acid elongases: structure, function, and implications in physiology and pathology